No abstract available
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Benzenesulfonates / administration & dosage
-
Benzenesulfonates / adverse effects
-
Bevacizumab
-
Cetuximab
-
Colonic Neoplasms / drug therapy
-
Diagnosis, Differential
-
Dose-Response Relationship, Drug
-
Drug Delivery Systems
-
Drug Eruptions / diagnosis*
-
ErbB Receptors / antagonists & inhibitors
-
Erlotinib Hydrochloride
-
Everolimus
-
Facial Dermatoses / chemically induced
-
Facial Dermatoses / diagnosis
-
Humans
-
Indoles / administration & dosage
-
Indoles / adverse effects
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / secondary
-
Male
-
Middle Aged
-
Neoplasms / drug therapy*
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Pyridines / administration & dosage
-
Pyridines / adverse effects
-
Pyrroles / administration & dosage
-
Pyrroles / adverse effects
-
Quinazolines / administration & dosage
-
Quinazolines / adverse effects
-
Sirolimus / administration & dosage
-
Sirolimus / adverse effects
-
Sirolimus / analogs & derivatives
-
Sorafenib
-
Sunitinib
-
Trastuzumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Benzenesulfonates
-
Indoles
-
Phenylurea Compounds
-
Pyridines
-
Pyrroles
-
Quinazolines
-
Niacinamide
-
Bevacizumab
-
temsirolimus
-
Everolimus
-
Sorafenib
-
Erlotinib Hydrochloride
-
EGFR protein, human
-
ErbB Receptors
-
Trastuzumab
-
Cetuximab
-
Sunitinib
-
Sirolimus